Clinical Trial Update: SOX as Salvage Treatment in Nasopharyngeal Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the SOX regimen (S-1 plus oxaliplatin) as salvage therapy for nasopharyngeal carcinoma; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Fudan University | Conditions: Nasopharyngeal Carcinoma | Phase 2 | Status: TERMINATED